ADiTx Therapeutics, Inc. Common Stock, also called ADITX Therapeutics, is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. Read More The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.